■神经胶质瘤是最具有药物和辐射抗性的肿瘤之一。胶质瘤患有肿瘤间和肿瘤内异质性,这使得相似治疗方案的结果因患者而异。本文旨在概述用于个体诊断的潜在成像标志物,预后,恶性胶质瘤的治疗反应预测。此外,对胶质瘤患者的影像学表现与生物学和临床信息的相关性进行综述。
■本研究的搜索策略是从PubMed等科学网站选择相关研究,Scopus,谷歌学者,和WebofScience直到2022年出版。它由诸如生物标记等关键词的组合组成,诊断,预后,成像技术,恶性神经胶质瘤,根据医学主题词。
■在神经胶质瘤管理中有效的一些成像参数包括:ADC,FA,Ktrans,局部脑血容量(rCBV),脑血流量(CBF),ve,Cho/NAA和乳酸/脂质比率,肿瘤内摄取18F-FET(用于诊断应用),RD,ADC,ve,vp,Ktrans,CBFT1,rCBV,肿瘤血流,Cho/NAA,乳酸/脂质,MI/Cho,18F-FET的吸收,11C-MET,和18F-FLT(用于预后和预测应用)。脑血容量和Ktrans与血管内皮生长因子(VEGF)等分子标志物有关。GBM肿瘤的术前ADCmin值与O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子甲基化状态相关。2-羟基戊二酸代谢物和动态18F-FDOPA正电子发射断层扫描摄取与异柠檬酸脱氢酶(IDH)突变有关。
■包括ADC在内的参数,RD,FA,rCBV,Ktrans,vp,摄取18F-FET有助于诊断,预后,脑胶质瘤的治疗反应预测。分子标志物如VEGF,MGMT,和具有一些扩散和灌注成像参数的IDH突变已被鉴定。
UNASSIGNED: Glioma is one of the most drug and radiation-resistant tumors. Gliomas suffer from inter- and intratumor heterogeneity which makes the outcome of similar treatment protocols vary from patient to patient. This article is aimed to overview the potential imaging markers for individual diagnosis, prognosis, and treatment response prediction in malignant glioma. Furthermore, the correlation between imaging findings and biological and clinical information of glioma patients is reviewed.
UNASSIGNED: The search strategy in this study is to select related studies from scientific websites such as PubMed, Scopus, Google Scholar, and Web of Science published until 2022. It comprised a combination of keywords such as Biomarkers, Diagnosis, Prognosis, Imaging techniques, and malignant glioma, according to Medical Subject Headings.
UNASSIGNED: Some imaging parameters that are effective in glioma management include: ADC, FA, Ktrans, regional cerebral blood volume (rCBV), cerebral blood flow (CBF), ve, Cho/NAA and lactate/lipid ratios, intratumoral uptake of 18F-FET (for diagnostic application), RD, ADC, ve, vp, Ktrans, CBFT1, rCBV, tumor blood flow, Cho/NAA, lactate/lipid, MI/Cho, uptakes of 18F-FET, 11C-MET, and 18F-FLT (for prognostic and predictive application). Cerebral blood volume and Ktrans are related to molecular markers such as vascular endothelial growth factor (VEGF). Preoperative ADCmin value of GBM tumors is associated with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. 2-hydroxyglutarate metabolite and dynamic 18F-FDOPA positron emission tomography uptake are related to isocitrate dehydrogenase (IDH) mutations.
UNASSIGNED: Parameters including ADC, RD, FA, rCBV, Ktrans, vp, and uptake of 18F-FET are useful for diagnosis, prognosis, and treatment response prediction in glioma. A significant correlation between molecular markers such as VEGF, MGMT, and IDH mutations with some diffusion and perfusion imaging parameters has been identified.